Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients.
allogeneic stem cell transplantation (allo-SCT)
donor lymphocyte infusion (DLI)
graft-versus-leukemia (GvL) effect
relapse
virus-specific T cells
α/β T depletion
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
23 Dec 2019
23 Dec 2019
Historique:
received:
11
10
2019
revised:
10
12
2019
accepted:
17
12
2019
entrez:
28
12
2019
pubmed:
28
12
2019
medline:
28
12
2019
Statut:
epublish
Résumé
Allogeneic stem cell transplantation (allo-SCT) is the preferred curative treatment for several hematological malignancies. The efficacy of allo-SCT depends on the graft-versus-leukemia (GvL) effect. However, the prognosis of patients with relapsed acute myeloid leukemia (AML) following allo-SCT is poor. Donor lymphocyte infusion (DLI) is utilized after allo-SCT in this setting to prevent relapse, to prolong progression free survival, to establish full donor chimerism and to restore the GvL effect in patients with hematological malignancies. Thus, there are different options for the administration of DLI in AML patients. DLI is currently used prophylactically and in the setting of an overt relapse. In addition, in the minimal residual disease (MRD) setting, DLI may be a possibility to improve overall survival. However, DLI might increase the risk of severe life-threatening complications such as graft-versus-host disease (GvHD) as well as severe infections. The transfusion of lymphocytes has been tested not only for the treatment of hematological malignancies but also chronic infections. In this context, manipulated DLI in a prophylactic or therapeutic approach are an option, e.g., virus-specific DLI using different selection methods or antigen-specific DLI such as peptide-specific CD8+ cytotoxic T lymphocytes (CTLs). In addition, T cells are also genetically engineered, using both chimeric antigen receptor (CAR) genetically modified T cells and T cell receptor (TCR) genetically modified T cells. T cell therapies in general have the potential to enhance antitumor immunity, augment vaccine efficacy, and limit graft-versus-host disease after allo-SCT. The focus of this review is to discuss the different strategies to use donor lymphocytes after allo-SCT. Our objective is to give an insight into the functional effects of DLI on immunogenic antigen recognition for a better understanding of the mechanisms of DLI. To ultimately increase the GvL potency without raising the risk of GvHD at the same time.
Identifiants
pubmed: 31878060
pii: jcm9010039
doi: 10.3390/jcm9010039
pmc: PMC7019914
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Bone Marrow Transplant. 2017 Dec;52(12):1623-1628
pubmed: 29035393
Nat Med. 2015 Aug;21(8):914-921
pubmed: 26193344
Clin Transplant. 2014 Aug;28(8):926-34
pubmed: 24931494
Int J Hematol. 2013 Nov;98(5):558-62
pubmed: 24142765
Biol Blood Marrow Transplant. 2013 Apr;19(4):507-8
pubmed: 23416853
Br J Haematol. 2019 Mar;184(5):782-787
pubmed: 30467839
Blood. 2012 Apr 5;119(14):3256-62
pubmed: 22337715
J Immunol. 2012 Sep 15;189(6):3198-208
pubmed: 22875800
Biol Blood Marrow Transplant. 2012 Sep;18(9):1415-21
pubmed: 22579634
Blood. 2010 Apr 8;115(14):2960-70
pubmed: 20103780
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Bone Marrow Transplant. 2016 Nov;51(11):1431-1438
pubmed: 27295272
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):708-715
pubmed: 29222325
Leukemia. 2012 Mar;26(3):381-9
pubmed: 21886171
Blood. 2018 Jan 11;131(2):247-262
pubmed: 28986344
Biol Blood Marrow Transplant. 2016 Feb;22(2):240-247
pubmed: 26256942
J Clin Oncol. 1997 Feb;15(2):433-44
pubmed: 9053463
Biol Blood Marrow Transplant. 2014 Jan;20(1):4-13
pubmed: 24018392
Ann Hematol. 2019 Jan;98(1):185-193
pubmed: 30143831
N Engl J Med. 2009 Jul 30;361(5):478-88
pubmed: 19641204
J Clin Oncol. 2016 Apr 1;34(10):1112-21
pubmed: 26811520
J Infect Dis. 1986 Mar;153(3):478-88
pubmed: 3005424
J Clin Invest. 2017 Feb 1;127(2):517-529
pubmed: 28067665
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Transpl Infect Dis. 2009 Oct;11(5):383-92
pubmed: 19558376
Bone Marrow Transplant. 2015 Sep;50(9):1227-34
pubmed: 26052909
Transfusion. 2011 Mar;51(3):591-9
pubmed: 21133926
J Clin Oncol. 2017 Nov 1;35(31):3547-3557
pubmed: 28783452
Br J Haematol. 2019 Jul;186(1):60-71
pubmed: 30916396
Blood. 2016 Jun 30;127(26):3350-9
pubmed: 27207792
Blood. 2012 Feb 9;119(6):1599-606
pubmed: 22167752
Blood. 2013 Aug 8;122(6):1087-8
pubmed: 23929838
Leuk Res. 2018 Sep;72:20-26
pubmed: 30064039
J Clin Invest. 2015 Jul 1;125(7):2677-89
pubmed: 26053664
Oncotarget. 2016 May 31;7(22):32579-91
pubmed: 27081039
Bone Marrow Transplant. 2016 May;51(5):663-7
pubmed: 26437060
Biol Blood Marrow Transplant. 2017 Feb;23(2):278-284
pubmed: 27816650
Int J Cancer. 2019 Mar 1;144(5):1135-1146
pubmed: 30006990
Bone Marrow Transplant. 1998 Dec;22(11):1057-63
pubmed: 9877267
J Virol. 2000 Sep;74(17):8140-50
pubmed: 10933725
N Engl J Med. 1994 Apr 28;330(17):1185-91
pubmed: 8093146
Cell. 2010 Sep 17;142(6):847-56
pubmed: 20850008
Clin Infect Dis. 2017 Jan 1;64(1):87-91
pubmed: 27682069
Blood. 2002 Jun 1;99(11):3916-22
pubmed: 12010789
Eur J Haematol. 2016 Jun;96(6):629-36
pubmed: 26260140
Biol Blood Marrow Transplant. 2017 Jun;23(6):938-944
pubmed: 28219836
Blood. 1991 Sep 1;78(5):1373-80
pubmed: 1652311
Blood. 2018 Mar 8;131(10):1063-1072
pubmed: 29358176
Lancet Haematol. 2017 Apr;4(4):e183-e191
pubmed: 28330607
JCI Insight. 2016;1(5):
pubmed: 27213183
Bone Marrow Transplant. 2014 Apr;49(4):567-71
pubmed: 24488048
Cancer Treat Rev. 2010 Nov;36(7):528-38
pubmed: 20381970
Haematologica. 2017 Nov;102(11):1810-1822
pubmed: 28883081
Blood. 2019 Mar 21;133(12):1290-1297
pubmed: 30578254
Biol Blood Marrow Transplant. 2015 Oct;21(10):1714-20
pubmed: 26172479
Leukemia. 2019 Sep;33(9):2208-2226
pubmed: 30872779
Cancer Immunol Immunother. 2018 Feb;67(2):311-325
pubmed: 29052782
Leukemia. 2015 Jan;29(1):1-10
pubmed: 24919807
Eur J Haematol. 2017 Apr;98(4):348-354
pubmed: 27893163
J Clin Oncol. 2007 Nov 1;25(31):4938-45
pubmed: 17909197
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
Blood. 2003 Dec 15;102(13):4255-60
pubmed: 12933590
Biol Blood Marrow Transplant. 2010 Aug;16(8):1037-69
pubmed: 20580849
Eur J Haematol. 2016 Mar;96(3):297-308
pubmed: 26010204
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Bone Marrow Transplant. 1998 Mar;21(6):543-51
pubmed: 9543057
Blood. 2017 Aug 3;130(5):677-685
pubmed: 28588018
Blood. 1999 Aug 15;94(4):1201-8
pubmed: 10438707
Leuk Res. 2011 Mar;35(3):363-8
pubmed: 20880586
Nat Med. 2013 Mar;19(3):372-7
pubmed: 23435170
Sci Transl Med. 2013 Feb 27;5(174):174ra27
pubmed: 23447018
Hematol Oncol Stem Cell Ther. 2011;4(4):149-56
pubmed: 22198185
Biol Blood Marrow Transplant. 2015 Jan;21(1):24-9
pubmed: 25452035
J Immunol Methods. 2016 Jul;434:73-82
pubmed: 27129808
Hematology. 2016 May;21(4):206-12
pubmed: 26907959
Nat Immunol. 2018 Sep;19(9):1037
pubmed: 29449629
J Clin Oncol. 2018 Apr 10;36(11):1175-1176
pubmed: 29412785
Leukemia. 2007 Dec;21(12):2512-8
pubmed: 17713545
Blood. 2016 Jan 7;127(1):62-70
pubmed: 26660427
Ann Hematol. 2018 Feb;97(2):335-342
pubmed: 29151133
Br J Haematol. 2003 Apr;121(1):109-18
pubmed: 12670340
Blood. 1995 Sep 1;86(5):2041-50
pubmed: 7655033
Br J Haematol. 2012 Feb;156(4):550-2
pubmed: 21981646
Sci Transl Med. 2010 Jul 21;2(41):41ra52
pubmed: 20650872
Blood. 2013 Jul 18;122(3):348-56
pubmed: 23673862
J Clin Oncol. 2012 Sep 10;30(26):3194-201
pubmed: 22869882
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
J Clin Oncol. 2002 Jan 15;20(2):405-12
pubmed: 11786567
N Engl J Med. 1995 Oct 19;333(16):1038-44
pubmed: 7675046
J Hematol Oncol. 2018 Oct 20;11(1):127
pubmed: 30342553
N Engl J Med. 1982 Jul 1;307(1):7-13
pubmed: 6281647
Blood. 1990 Dec 15;76(12):2462-5
pubmed: 2265242
Blood. 2012 May 31;119(22):5088-103
pubmed: 22403259
Biol Blood Marrow Transplant. 2016 Jul;22(7):1324-1329
pubmed: 27026249
Blood. 2004 Feb 15;103(4):1548-56
pubmed: 14576063
Biol Blood Marrow Transplant. 2015 Apr;21(4):653-60
pubmed: 25540937
Leuk Res. 2016 Oct;49:1-6
pubmed: 27505705
Biol Blood Marrow Transplant. 2018 Jul;24(7):1399-1405
pubmed: 29684563
Curr Stem Cell Res Ther. 2017;12(3):188-196
pubmed: 28025936
Bone Marrow Transplant. 2014 Feb;49(2):287-91
pubmed: 23933760
Blood. 1990 Feb 1;75(3):555-62
pubmed: 2297567
Blood. 2016 Mar 17;127(11):1502-8
pubmed: 26764356
Br J Haematol. 2019 May;185(3):570-573
pubmed: 30125934
Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12
pubmed: 14993886
Ann Hematol. 2017 May;96(5):829-838
pubmed: 28285386
Exp Hematol. 2010 Nov;38(11):1066-73
pubmed: 20637829
HLA. 2017 May;89(5):267-277
pubmed: 28371460
Biol Blood Marrow Transplant. 2018 Jan;24(1):71-77
pubmed: 28864137
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
Blood. 2017 Nov 2;130(18):1985-1994
pubmed: 28860210
Bone Marrow Transplant. 2015 May;50(5):690-5
pubmed: 25774594
J Clin Oncol. 2013 Jan 20;31(3):e44-7
pubmed: 23248243